|
|
Blood, 15 August 2007, Vol. 110, No. 4, pp. 1178-1183.
Prepublished online as a Blood First Edition Paper on April 17, 2007; DOI 10.1182/blood-2007-01-066043.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Monica Galli1,
Giovanna Borrelli2,
Eva Marie Jacobsen3,
Rosa Maria Marfisi2,
Guido Finazzi1,
Roberto Marchioli2,
Finn Wisloff3,
Stefana Marziali1,
Olivier Morboeuf4, and
Tiziano Barbui1
1 Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy;
2 Laboratory of Epidemiology, Istituto Mario Negri Sud, S. Maria Imbaro, Chieti, Italy;
3 Ulleval Hospital, Oslo, Norway;
4 Diagnostica Stago, Asnieres, France
To assess the clinical significance of lupus anticoagulants (LAs) and antiphospholipid antibodies (aPLs) toward thrombosis and abortions, we measured them in 112 patients whose samples were available at enrollment in the warfarin in the antiphospholipid syndrome (WAPS) study. Enzyme-linked immunosorbent assay (ELISA) and coagulation test values in the highest and lowest tertiles were compared. When considered separately, IgG antibodies to β2-glycoprotein I (aβ2GPI) and prothrombin (aPT) were associated with anamnestic arterial and venous thrombosis, respectively, and those to annexin AV (aAnAV) with abortions. IgM antibodies to protein S and the lupus ratio of the dilute prothrombin time were associated with prospective thrombosis. No other association for IgM antibodies was seen. LA-positive patients who carried aβ2GPI antibodies were at risk of anamnestic arterial and total thrombosis and aPT antibodies to that of anamnestic venous and total thrombosis. LA-positive patients who carried IgG aβ2GPI and aAnAV antibodies were at risk for both anamnestic abortion and prospective thrombosis. Overall, these data support the inclusion of aβ2GPI antibodies in and suggest the removal of anticardiolipin antibodies from the laboratory criteria of the antiphospholipid syndrome. They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Y. Chan, F. Andreotti, and R. C. Becker
Hypercoagulable States in Cardiovascular Disease
Circulation,
November 25, 2008;
118(22):
2286 - 2297.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M Patnaik, K. Wudhikarn, M. M Shroff, A. A Killeen, M. T. Reding, and R. S. Kasthuri
Spectrum of Antiphospholipid Antibodies and Associated Thrombotic and Obstetric Events among Patients with Antiphospholipid Syndrome
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
5343 - 5343.
[Abstract]
|
 |
|

|
 |

|
 |
 
S. M. Nelson and I. A. Greer
The potential role of heparin in assisted conception
Hum. Reprod. Update,
November 1, 2008;
14(6):
623 - 645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Forastiero and M Martinuzzo
Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome
Lupus,
October 1, 2008;
17(10):
872 - 877.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
I Giles, A Lambrianides, and A Rahman
Examining the non-linear relationship between monoclonal antiphospholipid antibody sequence, structure and function
Lupus,
October 1, 2008;
17(10):
895 - 903.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Borrell, I. Tirado, J. Mateo, A. Oliver, A. Santamaria, and J. Fontcuberta
IgM anti-protein S antibodies as a risk factor for venous thrombosis
Haematologica,
July 1, 2008;
93(7):
1115 - 1117.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Membre, D. Wahl, V. Latger-Cannard, J.-P. Max, P. Lacolley, T. Lecompte, and V. Regnault
The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies
Haematologica,
April 1, 2008;
93(4):
566 - 573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Diagnosing Antiphospholipid Antibody Syndrome
Journal Watch Oncology and Hematology,
September 11, 2007;
2007(911):
1 - 1.
[Full Text]
|
 |
|
|
|